TKT and small cell lung carcinoma: Antiangiogenic therapies including agents like bevacizumab, sorafenib, sunitinib, and surufatinib have shown limited efficacy, with the notable exception of the multitargeted tyrosine kinase (TK) inhibitor anlotinib.6–9 In the ALTER 1202 study, third-line anlotinib treatment significantly extended median PFS by 3.4 months in ES-SCLC, alongside improvements in mOS and disease control rate (DCR).10 This led to a National Medical Products Administration approval in 2019 for ES-SCLC in China in third-line settings or beyond.